Business Wire

VALBIOTIS Announces Positive Results From the Phase IIA Clinical Study of VALEDIA®, Now the First Product Proven Effective in People With Prediabetes


Regulatory News:

VALBIOTIS (Paris:ALVAL) (FR0013254851 – ALVAL / PEA/PME eligible), Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, today announced positive results (topline data) for the Phase IIA study1 of VALEDIA® (active substance: TOTUM-63), which evaluated this product's efficacy in a prediabetic population, compared to placebo. In this population, VALEDIA® significantly reduced fasting and post-prandial blood glucose levels, the two main risk factors for type 2 diabetes and the primary and secondary endpoints of the study, respectively. VALEDIA® also significantly reduced body weight and waist circumference. Thanks to these results, VALEDIA® is the first clinically validated product designed for prediabetic people, to reduce several risk factors for type 2 diabetes. These results enable the concomitant launch of the last two Phase IIB clinical studies (REVERSE-IT and PREVENT-IT), to obtain the first health claims for the risk reduction of type 2 diabetes in Europe and North America. This regulatory process does not require a Phase III study. Commercialization is planned for 2021, as previously announced.

Professor Jean-Marie BARD, Hospital Practitioner and Professor of Fundamental and Clinical Biochemistry at the University of Nantes, scientific expert for the study comments, "The reduction of fasting blood glucose and blood glucose 2 hours after a glucose intake is a new advance for prediabetics. These results show the impact of VALEDIA® on metabolism, with even a decrease in body weight and waist circumference, usually hard to demonstrate in clinical studies. With such data, VALEDIA® proves its efficacy to reduce type 2 diabetes risk factors.“

Murielle CAZAUBIEL, member of the board and Director of Development and Medical Affairs at VALBIOTIS, adds: "VALEDIA® was designed to carry out multiple actions on several metabolic targets, thanks to an original plant-based composition. This innovation has had clinical success in people with prediabetes: we now know that VALEDIA® acts on risk factors for type 2 diabetes. This study is a great success, and we'd like to express our thanks to all the volunteers who participated."

Main results of the VALEDIA® Phase IIA clinical study in prediabetic people

This multicenter study, conducted in Europe, evaluated TOTUM-63, the active ingredient of VALEDIA®, in prediabetic people for 6 months. It was a randomized, double-blind, placebo-controlled study. Included subjects received a daily dose of 5 grams of VALEDIA® while the control group received 5 grams of the placebo. Dietary habits and physical activity levels remained unchanged in both groups during the study. The inclusion criteria were strict to ensure the robustness of the study: the subjects had to have moderate hyperglycemia, hyperglycemia 2 hours after glucose dose (OGTT, Oral Glucose Tolerance Test), abdominal obesity and hypertriglyceridemia. With such characteristics, the included subjects were particularly at risk of fast and pejorative evolution. Analyses were conducted on 51 subjects, 13 in the placebo group and 38 in the VALEDIA® group, according to the unbalanced study design.

Main characteristics of the study population:
57.1 years old
Gender: 35 women and 16 men
Body Mass Index: 31.3 Kg/m2
Fasting glycemia: 1.26 g/L
2h-glycemia (OGTT): 1.85 g/L
Blood triglycerides: 1.78 g/L

• Main criterion met:

VALEDIA ® significantly reduced fasting blood glucose levels, compared to the placebo, after 6 months (p<0.05).


Fasting glycemia (g/L)


6 months variation (g/L)

Variation VALEDIA®
vs placebo 2

Placebo (n=13 subjects)

+ 0.09 (± 0.04)

- 9.3%

VALEDIA® (n=38 subjects)

- 0.04 (± 0.02)


Mean values (± SEM)


Moderate fasting hyperglycemia is the main risk factor for type 2 diabetes identified in people with prediabetes. With these results, VALBIOTIS defines the reduction of fasting blood glucose levels as the primary endpoint of the last two clinical studies that will be used to support requests for health claims in Europe, the United States and Canada.

• Secondary criteria met:

VALEDIA® significantly reduces blood glucose levels after 2 hours (post-prandial blood glucose), the second risk factor for type 2 diabetes, compared to the placebo (p<0.05).


2 hours OGTT glycemia (g/L)


6 months variation (g/L)

Variation VALEDIA®
vs placebo 2

Placebo (n=13 subjects)

+ 0.32 (± 0.17)

- 22.5%

VALEDIA® (n=38 subjects)

- 0.02 (± 0.07)


Mean values (± SEM)


VALEDIA® significantly reduced two anthropometric parameters, compared to the placebo: body weight (p< 0.05) and waist circumference (p< 0.001).


Body weight (Kg)


6 months variation (g/L)

Variation VALEDIA®
vs placebo 3

Placebo (n=13 subjects)

+ 1.83 (± 0.57)

- 1.9 Kg

VALEDIA® (n=38 subjects)

- 0.07 (± 0.42)


Mean values (± SEM)



Waist circumference (cm)


6 months variation (cm)

Variation VALEDIA®
vs placebo 3

Placebo (n=13 subjects)

+ 2.81 (± 0.65)

- 4.48 cm

VALEDIA® (n=38 subjects)

- 1.67 (± 0.73)


Mean values (± SEM)


Furthermore, safety data confirm that this plant-based product achieves perfect tolerance.

For Sébastien PELTIER, CEO of VALBIOTIS "The results of this clinical Phase IIA study exceed our expectations. They demonstrate that TOTUM-63, the active substance of VALEDIA®, reduces the two main risk factors for type 2 diabetes in people with prediabetes. This success validates the concomitant launch of the last two clinical studies for VALEDIA® to obtain the first health claims for the risk reduction of type 2 diabetes, in Europe and in North America. This major milestone strengthens our discussions with potential partners for marketing VALEDIA®. This is a critical milestone for VALBIOTIS: we have now scientifically validated in humans the efficacy of our new plant-based approach to prevent metabolic diseases. We would like to thank our teams, partners and shareholders. "

About TOTUM-63, the active substance of VALEDIA®

Prediabetes is an increasingly prevalent public health problem worldwide and recognized by international organizations such as the WHO, the American Diabetes Association and the International Diabetes Federation. Without effective treatment, 70% to 90% of prediabetic patients will develop type 2 diabetes.

VALEDIA® is the first clinically validated product specifically designed to help prediabetics to reduce the risk of developing type 2 diabetes. VALEDIA® is the only product that contains the active substance TOTUM-63, a unique and patented combination of 5 plant extracts that act synergistically to target the physiopathological mechanisms of type 2 diabetes.

TOTUM-63 has already shown perfect tolerance and safety during a Phase I/II clinical study conducted in healthy volunteers. The results of the first international randomized placebo-controlled study showed that TOTUM-63 reduces fasting blood glucose levels and blood glucose after 2 hours, two risk factors for type 2 diabetes in people with prediabetes.

All the results from the Phase IIA study, as well as all key company information are available in the updated corporate presentation, available here:


VALBIOTIS is a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases. Its products are made for major players in the health care sector. VALBIOTIS particularly focuses on solutions to prevent type 2 diabetes, NASH (nonalcoholic steatohepatitis), obesity and cardiovascular diseases.

VALBIOTIS was founded in La Rochelle in early 2014 and has formed numerous partnerships with top academic centers in France and abroad, including La Rochelle University, the CNRS and Clermont Auvergne University located in Clermont-Ferrand. These partnerships have enabled VALBIOTIS to benefit from strong financial leverage, particularly thanks to experts and technical partners who support its projects. The Company has established three sites in France – Périgny, La Rochelle (17) and Riom (63) – and an American office in Boston (MA).

VALBIOTIS is a member of the "BPI Excellence" network and received the "Innovative Company" status accorded by BPI France. VALBIOTIS has also been awarded "Young Innovative Company" status and has received major financial support from the European Union for its research programs by obtaining support from the European Regional Development Fund (ERDF). VALBIOTIS is a PEA-SME eligible company.

Find out more about VALBIOTIS:

ISIN code: FR0013254851
Mnemonic code: ALVAL


This press release contains forward-looking statements about VALBIOTIS' objectives, based on rational hypotheses and the information available to the company at the present time. However, in no way does this constitute a guarantee of future performance, and these projections can be reconsidered based on changes in economic conditions and financial markets, as well as a certain number of risks and doubts, including those described in the VALBIOTIS core document, filed with the French Financial Markets Regulator (AMF) on 5 April 2017 (application number I.17-012), as well as in the 2018 annual financial report, filed with AMF on 8 March 2019. This press release, as well as the information contained herein, does not constitute an offer to sell or subscribe to, or a solicitation to purchase or subscribe to, VALBIOTIS' shares or securities in any country.

1 ID-RCB Number: 2016-A00484-47
2 Difference of the means of individual variations expressed in %.
3 Difference of the means of individual variations.

Contact information

Carole Rocher / 
Marc Delaunay 
+33 5 46 28 62 58

Stéphane Ruiz 
+33 1 56 88 11 14

Guillaume De Chamisso 
+33 6 85 91 32 56

Rebecca John / Patrick Till 
+1 646 378 2935

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Schlumberger Announces Fourth-Quarter and Full-Year 2019 Results Conference Call6.12.2019 21:07:00 EETPress release

Schlumberger Limited (NYSE:SLB) will hold a conference call on January 17, 2020 to discuss the results for the fourth quarter and full year ending December 31, 2019. The conference call is scheduled to begin at 8:30 am US Eastern time and a press release regarding the results will be issued at 7:00 am US Eastern time. To access the conference call, listeners should contact the Conference Call Operator at +1 (844) 721-7241 within North America or +1 (409) 207-6955 outside of North America approximately 10 minutes prior to the start of the call and the access code is 4013483. A webcast of the conference call will be broadcast simultaneously at on a listen-only basis. Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast. Following the end of the conference call, a replay will be available at until February 17, 2020, and can be accessed by dialing +1 (866) 207-1041 within North Amer

BUFF STUDIO Globally Launches My Coloring, a Mobile 3D Pixel Art Coloring Book Game6.12.2019 16:00:00 EETPress release

BUFF STUDIO announced on December 5 that it launched My Coloring, a mobile 3D pixel art coloring book game, in 155 countries simultaneously. This press release features multimedia. View the full release here: BUFF STUDIO launched My Coloring, a mobile 3D pixel art coloring book game, in 155 countries simultaneously. My Coloring is a game that materializes a 3D pixel art coloring book on mobile devices. You can blow your stress away as you paint spaces in the order of numbers on the screen while reading calming messages. Relaxing background music you will listen during gameplay and its fairytale-like design will give you pleasure and happiness. You can download it for free on Google Play and the Apple App Store. (Graphic: Business Wire) Its Android and iOS versions were released at the same time so the users can download it for free on Google Play and the Apple App Store. My Coloring is a game that materializes a 3D pixel art col

Horizon8 Opens European Headquarters in Cork with Plans for up to 50 Jobs6.12.2019 15:00:00 EETPress release

Horizon8, an innovative, technology solutions company today opens its European headquarters in Cork, Ireland. Formerly called HengTian, the Company was created in 2004 as a strategic partnership between Boston based State Street, and Hangzhou based Insigma Technology and Zhejiang University. The new office in Cork will mark the first European office for Horizon8 adding to the company’s North American presence in Boston. An Tánaiste (Deputy Prime Minister), Simon Coveney, T.D. commenting on the opening said: “This announcement is great news for Cork and indeed Ireland. With up to 50 jobs planned, Horizon8 is placing a significant vote of confidence in the Irish Market and further demonstrates our competitive position in attracting Foreign Direct Investment. All of these roles will be for high-skilled workers, including engineers, developers and business consultants. As a Government, we have been committed to making sure that there is a strong pipeline of job opportunities outside of Dub

UAE Company Completes GBP 300 Million Investment in UK6.12.2019 12:58:00 EETPress release

Twenty14 Holdings, the hospitality investment arm of LuLu Group International, has completed investments of US$ 390 million in UK with the inauguration of the Great Scotland Yard in London today. The hotel will be open for business from December 9, 2019. The historic property was acquired in 2015 for GBP 110 million, and the makeover of the hotel involved a further GBP 50 million. In addition to the Great Scotland Yard, Twenty14 Holdings had acquired the celebrated Waldorf Astoria Edinburgh – The Caledonian in Scotland in 2018. This press release features multimedia. View the full release here: The Great Scotland Yard being formally inaugurated by Nicky Morgan, Secretary of State, Lord Jonathan Marland, Sir Edward Lister, UAE Ambassador HE Mansoor Abulhoul, Indian High Commissioner Ruchi Ghanshyam, Hyatt Hotels Global President & CEO Mark Hoplamazian in the presence of LuLu Group Chairman Yusuffali MA and Twenty14 Holdings MD Ad

Autodoc GmbH adapts its storage capacity to strong company growth6.12.2019 12:08:00 EETPress release

Autodoc, the benchmark in online retail for car spare parts in Europe, is expanding its logistics locations in Szczecin and Berlin. With above-average growth in recent years, the demands placed on logistics have become increasingly extensive. In 2018 as a whole, around five million orders were processed and delivered at the two Autodoc warehouses in Berlin and Szczecin. In the current year, the 6 million mark in orders was already exceeded by mid-November. In order to meet Europe-wide demand in the future as well, Autodoc has rented additional warehouse space in Szczecin and at its main location in Berlin. This press release features multimedia. View the full release here: The Autodoc warehouse in Szczecin, Poland, will provide around 27,000 m² of storage space from spring 2020. (Photo: Business Wire) Expansion of logistics capacities is a key growth factor Autodoc saw itself as a European company from the outset and identified

Play harnesses ADVA timing solution for 5G-ready mobile network6.12.2019 11:00:00 EETPress release

ADVA (FSE: ADV) today announced that Play has deployed its Oscilloquartz timing solution to provide LTE Advanced services throughout Poland and prepare its network for 5G. The PTP grandmaster with dual integrated GNSS antenna enables Play to deliver the resilient and accurate Precision Time Protocol (PTP) frequency and phase synchronization needed for next-generation connectivity. With its ultra-compact design, the OSA 5405 Series empowers Play to migrate its radio access network from costly GNSS RF antennas and coax cables to standard copper and fiber Ethernet cabling, dramatically reducing capital expenditure and operating expenses. ADVA’s long-term partner NAVI also played a key role in the project. This press release features multimedia. View the full release here: ADVA's OSA 5405 timing technology is helping Play prepare for 5G (Photo: Business Wire) “This deployment is about taking our RAN infrastructure to the next level.

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom